Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 4Other solid neoplasm 3Genitourinary 3Dermatologic 2

Conditions

Microsatellite Unstable Colorectal Cancer 1Mesothelioma 1Advanced or Metastatic Solid Tumors 1

Interventions

Nivolumab 3Ipilimumab 3pembrolizumab 2entrectinib 2cobimetinib 2Pemetrexed 2Cisplatin 2tovorafenib 1sotorasib 1relatlimab 1pralsetinib 1larotrectinib 1ipatasertib 1inavolisib 1daratumumab 1atezolizumab 1alectinib 1PM 01183 1Midazolam 1Carboplatin 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Ipilimumab × Other solid neoplasm × Clear all
NCT02060188 2025-11-06

CheckMate142

Bristol-Myers Squibb

Phase 2 Completed
385 enrolled 17 charts 2 FDA
GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT01928394 2024-12-27

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Completed
1,163 enrolled 33 charts 1 FDA
Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT02899299 2024-05-21

CheckMate743

Bristol-Myers Squibb

Phase 3 Completed
605 enrolled 17 charts 1 FDA
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡